Ocular Therapeutix, Inc. (OCUL) Financials
OCUL Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 252.1 million | 160.9 million |
2023-09-30 | 162.4 million | 154.5 million |
2023-06-30 | 122.6 million | 119.5 million |
2023-03-31 | 128.6 million | 118.9 million |
OCUL Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -17.7 million | 4.3 million |
2023-09-30 | -8.0 million | 4.5 million |
2023-06-30 | -22.1 million | 4.4 million |
2023-03-31 | -23.4 million | 4.6 million |
OCUL Net Income
No data available :(
OCUL Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 196.0 million | - | 8.5 million |
2023-09-30 | 110.6 million | - | 9.1 million |
2023-06-30 | 66.6 million | 53.3 million | 9.4 million |
2023-03-31 | 79.0 million | 54.7 million | 9.9 million |
OCUL Shares Outstanding
OCUL Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 459000 | 16.2 million | 43.7 million | 26.5 million |
2023-09-30 | 259000 | 15.0 million | 8.6 million | 9.3 million |
2023-06-30 | 2.0 million | 15.1 million | 8.2 million | 11.2 million |
2023-03-31 | 3.4 million | 14.7 million | 9.1 million | 10.8 million |
OCUL Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 14.8 million | 1.4 million |
2023-09-30 | 15.0 million | 1.4 million |
2023-06-30 | 15.2 million | 1.3 million |
2023-03-31 | 13.4 million | 1.2 million |
OCUL
Price: $6.17
52 week price:
Payout Ratio Range:
Earnings Per Share: -1.01 USD
P/E Ratio: -5.56
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 567800
Ebitda: -14.6 millionMarket Capitalization: 1.4 billion